Navigation Links
NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference
Date:11/23/2009

SANTA CLARA, Calif., Nov. 23 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that CEO, Dr. Branislav Vajdic, and CFO, Richard Brounstein, will present at the 2nd Annual LD MICRO Conference on Thursday, December 3rd, at 4:30 PM PST at the Luxe Sunset Hotel in Los Angeles.

Company management will be available for one-on-one meetings on Wednesday, December 2nd and Thursday, December 3rd. Please contact Brett Aimee Maas at (646) 536-7331 or brett@haydenir.com to request a meeting.

Dr. Branislav Vajdic, commented, "This year was one of accomplishments. Most notable was the launch of QTinno(TM), our fully automated solution for cardiac safety. And, our many efforts to reinforce our 3-D platform technology - including our wireless focus - should not go unnoticed. We have developed a disruptive technology to target a growing need and look forward to the opportunity to present our vision to this micro-cap investor audience."

About LD MICRO

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor.

For more information on the list of presenting companies or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0



Investor Contact:
Hayden Communications, Inc.
Jeff Stanlis, VP of Communications
(602) 476-1821
jeff@haydenir.com

SOURCE NewCardio, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference
2. Omnicell to Present at Piper Jaffray Healthcare Conference
3. Masimo to Present at the 21st Annual Piper Jaffray Health Care Conference
4. Smart Balance, Inc. CEO Presents at Citigroup Small and Midcap Conference
5. Morehead Presents Webinar on "How Physician Attitudes Impact Hospital Goals "
6. Highlights of NHLBI-supported research presented at American Heart Associations Scientific Sessions
7. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
8. Vivakor Presents at Nutraceutical Event
9. Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
10. California Consumer Attorney Mary Alexander to Present at 48th Annual COAC Convention
11. NOVAVAX to Present at the Influenza Congress USA 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... According to recent statistics, there are nearly ... physical therapy clinics. Each physical therapy professional and every clinic has a duty ... time, staying afloat in a competitive industry is also essential. The solution that many ...
(Date:5/31/2016)... Santa Barbara, CA (PRWEB) , ... May 31, 2016 , ... Throughout the day, adults ... soda for sustained motivation and awareness, but what they could be reaching for instead is ... green tea plants that are grown in Japan. This sacred tea is harvested from early ...
(Date:5/31/2016)... ... ... years ago it was revolutionary: enabling the people who hear distressing voices to speak ... approach has proven transformative, both for people who hear voices and for the field ... around the world, but it still lags in the United States. , Now, Gail ...
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... Francisco, CA (PRWEB) , ... May 31, 2016 , ... ... cases for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , ... durable waxed canvas or ballistic nylon, the Duo is smartly designed for ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: ... an extensive package consisting of a quality control set ... NGS System, reinforcing the proven accuracy of its next-generation ... and training for laboratories. QIAGEN has incorporated the Horizon ...
(Date:5/31/2016)... , May 31, 2016 ... market is progressing at a CAGR of 10.6% within ... was valued at US$0.46 bn in 2013. Owing to ... expected to reach US$0.88 bn by the end of ... derived from the market,s holistic representation in a research ...
(Date:5/31/2016)... ZIONA, Israel , May 31, 2016 ... company utilizing its proprietary plant-based rhCollagen technology for tissue ... from the Chief Scientist of Israel,s ... its NIS 12 million development project for 2016. The Chief ... than last year,s authorized grant, which totaled NIS 4.7 ...
Breaking Medicine Technology: